Please use this identifier to cite or link to this item:
Title: Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery
Authors: Lee, J.
Sohn, I.
Do, I.-G.
Kim, K.-M.
Park, S.H.
Park, J.O.
Park, Y.S.
Lim, H.Y.
Sohn, T.S.
Bae, J.M.
Choi, M.G.
Lim, D.H.
Min, B.H.
Lee, J.H.
Rhee, P.L.
Kim, J.J.
Choi, D.I.
Tan, I.B.
Das, K.
Tan, P. 
Jung, S.H.
Kang, W.K.
Kim, S.
Issue Date: 5-Mar-2014
Citation: Lee, J., Sohn, I., Do, I.-G., Kim, K.-M., Park, S.H., Park, J.O., Park, Y.S., Lim, H.Y., Sohn, T.S., Bae, J.M., Choi, M.G., Lim, D.H., Min, B.H., Lee, J.H., Rhee, P.L., Kim, J.J., Choi, D.I., Tan, I.B., Das, K., Tan, P., Jung, S.H., Kang, W.K., Kim, S. (2014-03-05). Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS ONE 9 (3) : -. ScholarBank@NUS Repository.
Abstract: Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-third of stage II gastric cancer (GC) patients developed recurrences. The aim of this study was to develop and validate a prognostic algorithm for gastric cancer (GCPS) that can robustly identify high-risk group for recurrence among stage II patients. A multi-step gene expression profiling study was conducted. First, a microarray gene expression profiling of archived paraffin-embedded tumor blocks was used to identify candidate prognostic genes (N = 432). Second, a focused gene expression assay including prognostic genes was used to develop a robust clinical assay (GCPS) in stage II patients from the same cohort (N = 186). Third, a predefined cut off for the GCPS was validated using an independent stage II cohort (N = 216). The GCPS was validated in another set with stage II GC who underwent surgery without adjuvant treatment (N = 300). GCPS was developed by summing the product of Cox regression coefficients and normalized expression levels of 8 genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, TFDP1). A prospectively defined cut-point for GCPS classified 22.7% of validation cohort treated with chemoradiotherapy (N = 216) as high-risk group with 5-year recurrence rate of 58.6% compared to 85.4% in the low risk group (hazard ratio for recurrence = 3.16, p = 0.00004). GCPS also identified high-risk group among stage II patients treated with surgery only (hazard ratio = 1.77, p = 0.0053). © 2014 Lee et al.
Source Title: PLoS ONE
ISSN: 19326203
DOI: 10.1371/journal.pone.0090133
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2014-nanostring-based_multigene_assay_predict_recurrence-published.pdf487.18 kBAdobe PDF




checked on Jun 13, 2021


checked on Jun 4, 2021

Page view(s)

checked on Jun 7, 2021


checked on Jun 7, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.